A review of data from seven clinical trials suggests that intensive glucose control is associated with reduced risk of microalbuminuria and macroalbuminuria (conditions characterized by excessive levels of protein in the urine usually resulting from damage to the filtering units of the kidneys), according to a report published in the May 28 issue of Archives of Internal Medicine, a JAMA Network publication.1

The meta-analysis also suggests the data “were inconclusive” that intensive glycemic control was related to reduced risk of significant clinical renal outcomes, such as doubling of the serum creatinine level, end-stage renal disease (ESRD) or death from renal disease during the trials’ follow-up years.

Aggressive glycemic control has been hypothesized to prevent renal disease in patients with type 2 diabetes mellitus (T2DM), according to the study background.

“Our analysis demonstrates that, after 163,828 patient-years of follow-up in the seven studies examined, intensive glycemic control lessens albuminuria, but data are lacking for evidence of a benefit for clinically important renal end points,” the authors note.

Compared with conventional control, intensive glucose control was associated with reduced risk of microalbuminuria (risk ratio, 0.86) and macroalbuminuria (0.74), but not doubling of the serum creatinine level (1.06), ESRD (0.69) or death from renal disease (0.99), according to study results.

“Acknowledging the low incidence of clinical renal outcomes coupled with the apparent lack of convincing benefit of intensive glycemic control to prevent CKD (chronic kidney disease) and ESRD in patients with newly diagnosed or existing T2DM, there is little compelling reason to initiate intensive glycemic control in midstage of the disease with the aim of preventing renal failure,” the authors conclude.

In an invited commentary2, David M. Nathan, M.D., of Massachusetts General Hospital, Harvard Medical School, Boston, writes: “The studies included in the meta-analysis by Coca et al, with the possible exception of the UKPDS [UK Prospective Diabetes Study Group] long-term follow-up, were far too brief to address the effects of intensive therapy on end-stage renal disease. Their short duration and low absolute rates of severe renal outcomes, acknowledged by the authors, preclude such an analysis.”

“Although implementing intensive therapy is difficult and imposes burden and expense, all of the primary data continue to support its long-term benefit,” Nathan concludes.

In an invited commentary3, Karen L. Margolis, M.D., M.P.H., and Patrick J. O’Connor, M.D., M.A., M.P.H., of HealthPartners Research Foundation, Minneapolis, Minn., write: “The analyses presented by Coca et al demonstrate the lack of evidence that intensive glycemic control reduces the kinds of advanced complications of major concern to patients, such as renal failure.”

“We conclude that for many patients with T2DM, the potential benefits of multidrug intensive glucose control regimens, which are only marginally supported by current evidence, must be weighed against the potential risks of such therapy (including hypoglycemia and possible increased mortality risks) as well as the potentially larger benefits of focusing clinical attention on other domains, such as blood pressure lowering, lipid control and smoking cessation,” they conclude.

References:

1. (Arch Intern Med. 2012;172[10]:761-769.

2. (Arch Intern Med. 2012:172[10]:769-770.

3. (Arch Intern Med. 2012:172[10]:770-772.

Dear Bankix Systems Readers, We’ll go straight to the point:
This is a fund-raising campaign.
We need your help to sustain our efforts and to remain online.
We want to keep writing the stories of the week for you free.
We want to keep providing all the other free services we offer.
Our goal is to enhance your mental and physical health.
We need your help to continue to be your go-to health media portal.
Your donations will help keep us online; every little helps.
Donate now. Thank you.

DISCLAIMER:Bankix Systems Ltd is the registered name of a Canadian firm since 2003, and bankixsystems.com is its OFFICIAL website. Besides these entities, we have no relationship with anyone, business, website, or any other entity anywhere in the world, claiming to be Bankix Systems, or using a similar name, and creating the impression that it has some connection with our company. We do not endorse and are therefore, not responsible for any act or lack thereof by any such entity. Bankix Systems Ltd is also not responsible for the content of the description of products and services linked to our site nor does it necessarily endorse them. The information here provided is not for diagnosing/treating your health concerns. Kindly contact your doctor or health care professional for all your healthcare requirements.